RecruitingNot ApplicableNCT06989086

FearLess in NeuroOncology

FearLess in Neuro-Oncology

Sponsor

Virginia Commonwealth University

Enrollment

112 participants

Start Date

Jun 24, 2025

Study Type

INTERVENTIONAL

Conditions

Caregiver Glioblastoma (GBM)Oligodendroglioma Astrocytoma Primary Malignant Brain Tumor

Summary

The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant brain tumor patients and caregivers

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a program called FearLess — designed to reduce the fear of cancer coming back — in people with malignant brain tumors and their caregivers. The program is delivered online (virtually). **You may be eligible if...** - You are 18 or older - You are a patient with a primary malignant brain tumor (grade II–IV) who is at least 2 weeks past a brain surgery or biopsy - OR you are a caregiver (non-professional) of such a patient - You have an elevated level of fear or distress about the cancer recurring - You primarily speak English - You have a stable internet connection for virtual sessions **You may NOT be eligible if...** - You have cognitive impairment that would prevent active engagement with the program - You are unable to consent or participate in virtual sessions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALFearless in Neuro-Oncology

FearLess is a newly developed, empirically-rooted, manualized psychological intervention consisting of an intake + 8 sessions delivered over a 12-week time period. It consists of weekly individual 60- to 90-minute virtual therapy sessions.

Locations(1)

Virginia Commonwealth University

Richmond, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06989086

Related Trials

PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas

NCT051901721 location

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

NCT073265664 locations

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

NCT075608651 location

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

NCT0680530516 locations

NK Cell Therapy for Malignant Solid Brain Tumors

NCT075522334 locations